Park et al. analyzed 313 Korean women with BC in 1994 – 2000 with a median follow-up of 93 months and found that BM was most commonly in HR+/HER2− (54.3%), HR+/HER2+ (50.0%), HR−/HER2+ (42.9%) and least in HR−/HER2− (12.5%) patients (p = 0.04) [17]. This evidence concerns the gene ERBB2 and breast cancer.